359 related articles for article (PubMed ID: 26495976)
1. Relationship between Humoral Immune Responses against HPV16, HPV18, HPV31 and HPV45 in 12-15 Year Old Girls Receiving Cervarix® or Gardasil® Vaccine.
Godi A; Bissett SL; Miller E; Beddows S
PLoS One; 2015; 10(10):e0140926. PubMed ID: 26495976
[TBL] [Abstract][Full Text] [Related]
2. Neutralizing and cross-neutralizing antibody titres induced by bivalent and quadrivalent human papillomavirus vaccines in the target population of organized vaccination programmes.
Barzon L; Squarzon L; Masiero S; Pacenti M; Marcati G; Mantelli B; Gabrielli L; Pascucci MG; Lazzarotto T; Caputo A; Palù G
Vaccine; 2014 Sep; 32(41):5357-62. PubMed ID: 25045814
[TBL] [Abstract][Full Text] [Related]
3. Durability of the neutralizing antibody response to vaccine and non-vaccine HPV types 7 years following immunization with either Cervarix® or Gardasil® vaccine.
Godi A; Panwar K; Haque M; Cocuzza CE; Andrews N; Southern J; Turner P; Miller E; Beddows S
Vaccine; 2019 Apr; 37(18):2455-2462. PubMed ID: 30926298
[TBL] [Abstract][Full Text] [Related]
4. A randomized, observer-blinded immunogenicity trial of Cervarix(®) and Gardasil(®) Human Papillomavirus vaccines in 12-15 year old girls.
Draper E; Bissett SL; Howell-Jones R; Waight P; Soldan K; Jit M; Andrews N; Miller E; Beddows S
PLoS One; 2013; 8(5):e61825. PubMed ID: 23650505
[TBL] [Abstract][Full Text] [Related]
5. Cross-neutralizing antibodies elicited by the Cervarix® human papillomavirus vaccine display a range of Alpha-9 inter-type specificities.
Bissett SL; Draper E; Myers RE; Godi A; Beddows S
Vaccine; 2014 Feb; 32(10):1139-46. PubMed ID: 24440205
[TBL] [Abstract][Full Text] [Related]
6. Cross-protective vaccine efficacy of the bivalent HPV vaccine against HPV31 is associated with humoral immune responses: results from the Costa Rica Vaccine Trial.
Safaeian M; Kemp TJ; Pan DY; Porras C; Rodriguez AC; Schiffman M; Cortes B; Katki H; Wacholder S; Schiller JT; Gonzalez P; Penrose K; Lowy DR; Quint W; van Doorn LJ; Herrero R; Hildesheim A; Pinto LA
Hum Vaccin Immunother; 2013 Jul; 9(7):1399-406. PubMed ID: 23571174
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the immunogenicity of Cervarix® and Gardasil® human papillomavirus vaccines for oncogenic non-vaccine serotypes HPV-31, HPV-33, and HPV-45 in HIV-infected adults.
Toft L; Tolstrup M; Müller M; Sehr P; Bonde J; Storgaard M; Østergaard L; Søgaard OS
Hum Vaccin Immunother; 2014; 10(5):1147-54. PubMed ID: 24553190
[TBL] [Abstract][Full Text] [Related]
8. Sustained Antibody Responses 6 Years Following 1, 2, or 3 Doses of Quadrivalent Human Papillomavirus (HPV) Vaccine in Adolescent Fijian Girls, and Subsequent Responses to a Single Dose of Bivalent HPV Vaccine: A Prospective Cohort Study.
Toh ZQ; Russell FM; Reyburn R; Fong J; Tuivaga E; Ratu T; Nguyen CD; Devi R; Kama M; Matanitobua S; Tabrizi SN; Garland SM; Sinha R; Frazer I; Tikoduadua L; Kado J; Rafai E; Mulholland EK; Licciardi PV
Clin Infect Dis; 2017 Apr; 64(7):852-859. PubMed ID: 28034886
[TBL] [Abstract][Full Text] [Related]
9. Pre-clinical immunogenicity of human papillomavirus alpha-7 and alpha-9 major capsid proteins.
Bissett SL; Mattiuzzo G; Draper E; Godi A; Wilkinson DE; Minor P; Page M; Beddows S
Vaccine; 2014 Nov; 32(48):6548-55. PubMed ID: 25203446
[TBL] [Abstract][Full Text] [Related]
10. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12-24 in a Phase III randomized study of healthy women aged 18-45 years.
Einstein MH; Baron M; Levin MJ; Chatterjee A; Fox B; Scholar S; Rosen J; Chakhtoura N; Meric D; Dessy FJ; Datta SK; Descamps D; Dubin G;
Hum Vaccin; 2011 Dec; 7(12):1343-58. PubMed ID: 22048173
[TBL] [Abstract][Full Text] [Related]
11. Displaying 31RG-1 peptide on the surface of HPV16 L1 by use of a human papillomavirus chimeric virus-like particle induces cross-neutralizing antibody responses in mice.
Chen X; Zhang T; Liu H; Hao Y; Liao G; Xu X
Hum Vaccin Immunother; 2018; 14(8):2025-2033. PubMed ID: 29683766
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive Assessment of the Antigenic Impact of Human Papillomavirus Lineage Variation on Recognition by Neutralizing Monoclonal Antibodies Raised against Lineage A Major Capsid Proteins of Vaccine-Related Genotypes.
Godi A; Boampong D; Elegunde B; Panwar K; Fleury M; Li S; Zhao Q; Xia N; Christensen ND; Beddows S
J Virol; 2020 Nov; 94(24):. PubMed ID: 32967963
[TBL] [Abstract][Full Text] [Related]
13. Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines.
Jagu S; Karanam B; Gambhira R; Chivukula SV; Chaganti RJ; Lowy DR; Schiller JT; Roden RB
J Natl Cancer Inst; 2009 Jun; 101(11):782-92. PubMed ID: 19470949
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years.
Einstein MH; Baron M; Levin MJ; Chatterjee A; Edwards RP; Zepp F; Carletti I; Dessy FJ; Trofa AF; Schuind A; Dubin G;
Hum Vaccin; 2009 Oct; 5(10):705-19. PubMed ID: 19684472
[TBL] [Abstract][Full Text] [Related]
15. Sensitivity of Human Papillomavirus (HPV) Lineage and Sublineage Variant Pseudoviruses to Neutralization by Nonavalent Vaccine Antibodies.
Godi A; Kemp TJ; Pinto LA; Beddows S
J Infect Dis; 2019 Nov; 220(12):1940-1945. PubMed ID: 31412122
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the immunogenicity and reactogenicity of Cervarix and Gardasil human papillomavirus vaccines in HIV-infected adults: a randomized, double-blind clinical trial.
Toft L; Storgaard M; Müller M; Sehr P; Bonde J; Tolstrup M; Østergaard L; Søgaard OS
J Infect Dis; 2014 Apr; 209(8):1165-73. PubMed ID: 24273179
[TBL] [Abstract][Full Text] [Related]
17. Developments in L2-based human papillomavirus (HPV) vaccines.
Schellenbacher C; Roden RBS; Kirnbauer R
Virus Res; 2017 Mar; 231():166-175. PubMed ID: 27889616
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity assessment of HPV16/18 vaccine using the glutathione S-transferase L1 multiplex serology assay.
Robbins HA; Waterboer T; Porras C; Kemp TJ; Pawlita M; Rodriguez AC; Wacholder S; Gonzalez P; Schiller JT; Lowy DR; Esser M; Matys K; Poncelet S; Herrero R; Hildesheim A; Pinto LA; Safaeian M
Hum Vaccin Immunother; 2014; 10(10):2965-74. PubMed ID: 25483632
[TBL] [Abstract][Full Text] [Related]
19. Sustainability of neutralising antibodies induced by bivalent or quadrivalent HPV vaccines and correlation with efficacy: a combined follow-up analysis of data from two randomised, double-blind, multicentre, phase 3 trials.
Mariz FC; Gray P; Bender N; Eriksson T; Kann H; Apter D; Paavonen J; Pajunen E; Prager KM; Sehr P; Surcel HM; Waterboer T; Müller M; Pawlita M; Lehtinen M
Lancet Infect Dis; 2021 Oct; 21(10):1458-1468. PubMed ID: 34081923
[TBL] [Abstract][Full Text] [Related]
20. Characterization of the HPV-specific memory B cell and systemic antibody responses in women receiving an unadjuvanted HPV16 L1 VLP vaccine.
Dauner JG; Pan Y; Hildesheim A; Harro C; Pinto LA
Vaccine; 2010 Jul; 28(33):5407-13. PubMed ID: 20591543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]